Clinical trials: Crohns Disease
Crohn Disease, Fibrostenotic Crohn's Disease
Artificial Intelligence For Outcomes Research in Crohn's Disease: Digital Pathology Assessment of Fibrosis and Association With Patient History and Clinical Outcomes
The goal of this retrospective observational study is to learn whether artificial intelligence-based digital pathology can measure intestinal fibrosis and help identify patients with Crohn's disease who may be at greater risk of…
- Conditions
- Crohn Disease, Fibrostenotic Crohn's Disease, CD - Crohn's Disease
- Trial name
- AIFOR-CD (NCT07795476)
- Testing
- Ph-FCS(Muc) fibrosis severity Digital Pathology biomarker
- Where
- 2 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PharmaNest, Inc
Crohn's Disease
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's disease affecting ileum, ileocecal region…
- Trial name
- NCT01514240
- Testing
- D9421-C capsule 3 mg, Mesalazine tablets
- Where
- 25 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis (RA), Inflammatory Bowel Disease - IBD1
Phase I Clinical Study of ZL-82 Tablets
ZL-82 is an oral janus kinase (JAK) inhibitor. In vitro biological mass spectrometry identification test proves that ZL-82 can selectively and irreversibly inhibit JAK3.
- Trial name
- NCT06055023
- Testing
- ZL-82 12.5mg, ZL-82 25mg, ZL-82 50mg
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Crohn's Disease
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
- Trial name
- CAPE (NCT02130362)
- Where
- 148 sites in United States, Bosnia and Herzegovina and 20 more
- Volunteers
- 1,446 people
- Sponsor
- AbbVie
Crohn's Disease
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
The study will continue to assess the safety of certolizumab pegol (CDP870) as well as examine the evolution of long term efficacy in Crohn's disease patients who completed study C87042 [NCT00308581].
- Trial name
- Welcome2 (NCT00333788)
- Testing
- Certolizumab pegol (CDP870)
- Where
- 65 sites in United States, Austria and 10 more
- Volunteers
- 233 people
- Sponsor
- UCB Pharma
Crohn's Disease
A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects
This is an open-label, single dose, randomized, five-period, crossover study in healthy volunteers to assess the relative bioavailability of four GSK developed oral formulations of GSK1605786 relative to the capsule formulation…
- Trial name
- NCT01114607
- Testing
- GSK1605786 ChemoCentryx: formulation A, GSK1605786 GSK: formulation B, GSK1605786 GSK direct-fill: formulation C
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Crohn's Disease
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels.
- Trial name
- AFFIRM (NCT06063967)
- Testing
- Risankizumab SC
- Where
- 179 sites in United States, Argentina and 18 more
- Volunteers
- 289 people
- Sponsor
- AbbVie
Inflammatory Bowel Disease (IBD)
SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease
This is an exploratory, open-label, uncontrolled, multi-center, 1-arm study conducted at 16 sites in Bulgaria, Germany and Romania. A total of ca.
- Trial name
- ENTRANCE (NCT00820365)
- Testing
- SC12267 (4SC-101)
- Where
- 16 sites in Bulgaria, Germany and 1 more
- Volunteers
- 34 people
- Sponsor
- 4SC AG
Fistulizing Crohn's Disease
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
The primary objective of this study is to evaluate the efficacy of filgotinib as compared to placebo in establishing combined fistula response at Week 24.
- Trial name
- Divergence2 (NCT03077412)
- Testing
- Filgotinib
- Where
- 27 sites in United States, Austria and 7 more
- Volunteers
- 57 people
- Sponsor
- Gilead Sciences
Crohn's Disease, Inflammatory Bowel Disease
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.
- Trial name
- NCT01009281
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Colitis, Ulcerative, Crohn Disease
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group.
- Trial name
- NCT07483073
- Testing
- Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
- Where
- 70 sites in United States, Belgium and 8 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Crohn Disease
A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease
This is a study in adults with Crohn's Disease who also have fistulas near the anus. The study has 2 parts. The first part is to find out more about what causes the fistulas.
- Trial name
- NCT03752970
- Testing
- Spesolimab
- Where
- 10 sites in Austria, Belgium and 6 more
- Volunteers
- 27 people
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
The purpose of the study is to assess efficacy, safety and tolerability of 2 dose regimens of certolizumab pegol
- Trial name
- NCT04643483
- Testing
- Certolizumab pegol, Adalimumab
- Sponsor
- UCB Biopharma SRL
Crohn's Disease
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels.
- Trial name
- Target CD (NCT06548542)
- Testing
- Risankizumab, Lutikizumab, Trosunilimab
- Where
- 255 sites in United States, Austria and 31 more
- Volunteers
- 590 people
- Sponsor
- AbbVie
Colitis, Ulcerative
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
"GSK4528287 is a drug being developed to treat like inflammatory bowel diseases like Crohns disease and ulcerative colitis. This study is the first time that GSK4528287 will be given to humans.
- Trial name
- NCT06681181
- Testing
- GSK4528287
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Crohn's Disease
Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat Crohn's disease in patients with at least one perianal fistula.
- Trial name
- NCT00267709
- Testing
- Visilizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Facet Biotech
Crohn Disease
Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
The primary objective of this extension study was to obtain long-term safety data for BIRB 796 BS in patients with moderate to severe Crohn's disease after 26 weeks of treatment.
- Trial name
- NCT02209792
- Testing
- BIBR 796 BS, 5 mg, BIBR 796 BS, 20 mg
- Volunteers
- 284 people
- Sponsor
- Boehringer Ingelheim
Crohn Disease
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.
- Trial name
- NCT00206674
- Testing
- Sargramostim (Leukine)
- Where
- 70 sites in Argentina, Australia and 7 more
- Volunteers
- 286 people
- Sponsor
- Genzyme, a Sanofi Company
Crohn's Disease
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
The purpose of this study is to investigate the efficacy, safety and pharmacokinetics after dose escalation in Japanese subjects with Crohn's Disease.
- Trial name
- NCT01958827
- Testing
- Adalimumab
- Volunteers
- 28 people
- Sponsor
- AbbVie
Crohn's Disease
Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients
The objectives of this study were to assess the safety and tolerability of LDP-02 in patients with active Crohn's disease who were not receiving corticosteroids or immunosuppressives, to assess the ability of LDP-02 to reduce…
- Trial name
- NCT00655135
- Testing
- LDP-02
- Volunteers
- 185 people
- Sponsor
- Millennium Pharmaceuticals, Inc.